Home / People / Carina Healy
Portrait ofCarina Healy

Carina Healy


CMS Cameron McKenna Nabarro Olswang LLP
1 West Regent Street
G2 1AP
United Kingdom
Languages English

Carina Healy is partner in our Technology team with over 20 years experience advising on commercial and IP related transactions. She specialises in lifesciences and acts for a range of biotech, speciality pharma, medical device and medical technology companies. She also has a focus on academic institutions, having worked closely with long standing clients University of Glasgow, Dundee University, and University College London for many years.

Carina regularly advises her clients on large, complex and strategically important IP and commercial arrangements, including in and out licensing, clinical trials, strategic alliances, technology development collaborations, and manufacturing, supply and distribution agreements.  She is known for being commercial and pragmatic in finding ways to help her clients and their partners achieve outcomes which are beneficial for both parties

more less

"Carina is very strong in all areas."

Chambers, 2024

"She is exceptionally helpful and has brilliant knowledge of both our university and the higher education sector. She is a trusted adviser to us and provides helpful input on strategic issues, drawing on her broader experience of the sector."

Chambers, 2024

"has tremendous capacity to manage large and complex transactions, to distil the key risks, and to identify commercially sensible, pragmatic solutions"

Chambers UK

Relevant experience

  • Roslin Biomed (the “Dolly the Sheep” company) through its lifecycle and on its acquisition by Geron Corp.
  • NuCana BioMed on the in-licensing and acquisition of ProTides technology from Morvus and on its subsequent agreements for pre-clinical and clinical development of NuCana’s proprietary oncology products, including Acelarin.
  • Evexar Medical on the manufacturing and supply arrangements for its premium, single use, self-illuminated medical devices and on the supply arrangements for human tissue scaffold products
  • Consilient Health Limited on the distribution arrangements for Rewisca®.
  • Advising on the establishment and operation of the Stratified Medicine Scotland Innovation Centre, a collaborative venture between 4 universities, 4 health boards and 2 industrial partners, including drafting the consortium agreement, and negotiating agreements with suppliers of bioinformatics equipment/ next generation sequencing technology.
  • UCL Business on an investment of $20m by now MeiraGTx into Athena Vision, a spin out company established to develop gene therapy products for ocular conditions, including negotiating and advising UCLB on a complex collaboration, development and licence agreement with Meira.
  • Advising on the complex contractual, IP and revenue sharing arrangements for BloodPharma, a large multi-party research collaboration funded by Wellcome Trust, for the use of stem cells in the manufacture of red blood cells.
  • Glasgow University on many complex IP licensing arrangements over 18 years, including the licensing of vaccines to Wyeth and licensing genetically engineered seed strains to Bayer.
  • Dundee University on the arrangements for a large phase IV clinical trial conducted through the Scottish Primary Care Network for a global pharmaceutical company.
  • Yantai Jereh, a Chinese oil and gas company, on the in-licensing of various products and technologies from Plexus Plc for development and commercialisation in various Asian markets.
more less


  • 1995 - Law, Dip LP. University of Glasgow, Glasgow
  • 1994 - Law, LLB (Hons), University of Glasgow, Glasgow
  • Dual Qualified in Scots and English Law
more less


Scotland: Building opportunities
CMS Scotland worked with a number of key industry leaders and surveyed over 100 executives of four of Scotland’s most important future industry sectors to create our Thought Leadership report Scotland:...
The Future Fund matches Funding for Startups
The government announced financial support for start-ups totalling around £1.25bn. The package consists of two separate pots of money. The first, which launches in May and is named the Future Fund, is...
World First as AI-designed Drug Starts Clinical Trials 
The UK-based AI drug discovery company, Exscientia, has been hailed as reaching a huge milestone: the world’s first AI-designed drug to enter Phase 1 clinical trials. Why is this a big deal? And are...
Labour proposes Life Sciences Revolution
As summarised in our earlier article, here, Jeremy Corbyn has made radical proposals to change the United Kingdom’s life sciences industry and patent regime. The proposals impact the research and development...
Life Sciences Sector Specialists
CMS has a dedicated team of Life sciences Sector specialists providing local knowledge and understanding from international legal experts on the key regional issues in the sector. CMS Global Life Sciences...
Distribution law in Scotland
Agency Agreement Generally speaking, the law of Agency Agreements in Scotland is aligned with the law of Agency Agreements in England and Wales. Please see the section on ‘England and Wales’ for...
Commercial Contracts Bulletin – September 2019 edition
In this issue of the Commercial Contracts Bulletin, we take a look at a number of recent court decisions, including topics relating to enforceability of restrictive covenants; the dangers of acting where...
Frustrated by Brexit?
In Canary Wharf (BP4) T1 Ltd v European Medicines Agency [2019] EWHC 335 (Ch) the High Court ruled that The European Medicines Agency (the “EMA”) cannot use the United Kingdom’s upcoming exit from...
Commercial Contracts Bulletin – May 2019 edition
In the May issue of the Commercial Contracts Bulletin, we take a look at a number of recent court decisions, including topics relating to entire agreement clauses, whether Brexit is a frustrating event...
University ordered to disclose children’s clinical trial data 
In The University of Bristol v John Peters and The Information Commissioner EA/2018/0142, the First-Tier Tribunal held that anonymised clinical trial data is not exempt from disclosure under The Freedom...
Commercial Contracts Bulletin – January 2019 edition
In this issue of the Commercial Contracts Bulletin, we take a look at a number of recent court decisions, including topics relating to rescission for fraudulent mis­rep­res­ent­a­tion, termination of a contract...
Launch of Life Sciences Sector Deal 2
The Industrial Strategy – Life Sciences Sector Deal 2 report is broken down by themes with each identifying what progress has been made by each of the sector and Government. A summary of these themes...